Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer

Luca Giovanella, Massimo Castellani, Sergio Suriano, Teresa Ruberto, Luca Ceriani, Luca Tagliabue, Giovanni Lucignani

Research output: Contribution to journalArticle

Abstract

Aim. The aimof this study was to compare the diagnostic performance of whole-body bone scintigraphy (WBS) and multi-field-of-view single photon emission tomography (multi-FOV SPECT) with 99mTc-oxidronate ( 99mTc-HDP) in patients with prostate cancer (PCa). Methods. In a prospective study, WBS and SPECT acquisitions were performed in 194 patients with histologically confirmed PCa and serumprostate-specific antigen (PSA) levels above 10 ng/mL. Scans obtained using the two modalities were interpreted separately. Clinical and biochemical follow-up, radiological studies and biopsies served as benchmarks for the assessments. The impact of PSA level on WBS and SPECT results was also evaluated. Results. The patient-based sensitivity, specificity, accuracy, PPV and NPV values of SPECT examinations were higher than those of WBS, especially in patients with serum PSA levels

Original languageEnglish
Pages (from-to)629-633
Number of pages5
JournalTumori
Volume97
Issue number5
Publication statusPublished - Sep 2011

Keywords

  • Tc-oxidronate
  • Bone metastases
  • Prostate cancer
  • Single photon emission tomography

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Giovanella, L., Castellani, M., Suriano, S., Ruberto, T., Ceriani, L., Tagliabue, L., & Lucignani, G. (2011). Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer. Tumori, 97(5), 629-633.